In mice, production of plasma IL-1 and IL-6 in response to MPTP is related to behavioral lateralization

Brain Research

Volumn 1045, Issue 1-2, 2005, Pages 31-37

  Shen, Yan Qin ^a,b   Hebert, Guillaume ^b   Su, Yun ^a   Moze, Elizabeth ^b   Neveu, Pierre J ^b   Li, Kang Sheng ^a  

^a SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^b INSTITUT FRANÇOIS MAGENDIE   (France)

Author keywords

1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Blood; Brain asymmetry; Interleukin 1 ; Interleukin 6; Mouse

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 DIHYDROXYPHENYLACETIC ACID; DOPAMINE; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CONCENTRATION (PARAMETERS); DECAPITATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; STRIATE CORTEX;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; BRAIN; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; ENCEPHALITIS; FORELIMB; FUNCTIONAL LATERALITY; INTERLEUKIN-1; INTERLEUKIN-6; MALE; MICE; MICE, INBRED C57BL; MOVEMENT; PARKINSONIAN DISORDERS;

EID: 19444377708     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2005.03.009     Document Type: Article

References (38)

1. A. Abdelgabar, and J. Sharma Sleep disorders in Parkinson's disease Int. J. Clin. Pract. 57 2003 781 787
2. Y. Araki, A. Andoh, Y. Fujiyama, K. Hata, J. Makino, T. Okuno, F. Nakanura, and T. Bamba Application of 2-aminopyridine fluorescence labeling in the analysis of in vivo and in vitro metabolism of dextran sulfate sodium by size-exclusion high-performance liquid chromatography J. Chromatogr., B: Biomed. Sci. Appl. 753 2001 209 215
3. C. Barcia, A. Fernandez Barreiro, M. Poza, and M.T. Herrero Parkinson's disease and inflammatory changes Neurotox. Res. 5 2003 411 418
4. S. Basu, P.S. Dasgupta, and J.R. Chowdhury Enhanced tumor growth in brain dopamine-depleted mice following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment J. Neuroimmunol. 60 1995 1 8
5. H. Bessler, R. Djaldetti, H. Salman, M. Bergman, and M. Djaldetti IL-1 beta, IL-2, IL-6 and TNF-alpha production by peripheral blood mononuclear cells from patients with Parkinson's disease Biomed. Pharmacother. 53 1999 141 145
6. L. Carr, A. Tucker, and R. Fernandez-Botran The enhancement of T cell proliferation by L-dopa is mediated peripherally and does not involve interleukin-2 J. Neuroimmunol. 142 2003 166 169
7. R.L. Collins On the inheritance of direction and degree of asymmetry S.D. Glick Cerebral Lateralization in Non human Species 1985 Academic Press New York 41 71
8. A. Czlonkowska, I. Kurkowska-Jastrzebska, A. Czlonkowski, D. Peter, and G.B. Stefano Immune processes in the pathogenesis of Parkinson's disease-a potential role for microglia and nitric oxide Med. Sci. Monit. 8 2002 RA165 RA177
9. C. Da Cunha, M.E. Angelucci, N.S. Canteras, S. Wonnacott, and R.N. Takahashi The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities Cell. Mol. Neurobiol. 22 2002 227 237
10. T. Di Paolo, P. Bedard, M. Daigle, and R. Boucher Long-term effects of MPTP on central and peripheral catecholamine and indoleamine concentrations in monkeys Brain Res. 379 1986 286 293
11. J. Dong, O. Mrabet, E. Moze, K. Li, and P.J. Neveu Lateralization and catecholaminergic neuroimmunomodulation: prazosin, an alpha1/alpha2-adrenergic receptor antagonist, suppresses interleukin-1 and increases interleukin-10 production induced by lipopolysaccharides Neuroimmunomodulation 10 2002 163 168
12. J. Fernandez-Ruiz, D.J. Doudet, and T.G. Aigner Long-term cognitive impairment in MPTP-treated rhesus monkeys NeuroReport 7 1995 102 104
13. U. Fiszer, K. Piotrowska, J. Korlak, and A. Czlonkowska The immunological status in Parkinson's disease Med. Lab. Sci. 48 1991 196 200
14. U. Fiszer, E. Mix, S. Fredrikson, V. Kostulas, T. Olsson, and H. Link Gamma delta+ T cells are increased in patients with Parkinson's disease J. Neurol. Sci. 121 1994 39 45
15. M.X. Gao, K. Li, J. Dong, S. Liege, B. Jiang, and P.J. Neveu Strain-dependent association between lateralization and lipopolysaccharide- induced IL-1beta and IL-6 production in mice Neuroimmunomodulation 8 2000 78 82
16. M.C. Ghosh, A.C. Mondal, S. Basu, S. Banerjee, J. Majumder, D. Bhattacharya, and P.S. Dasgupta Dopamine inhibits cytokine release and expression of tyrosine kinases, Lck and Fyn in activated T cells Int. Immunopharmacol. 3 2003 1019 1026
17. Y. Hasegawa, T. Inagaki, M. Sawada, and A. Suzumura Impaired cytokine production by peripheral blood mononuclear cells and monocytes/macrophages in Parkinson's disease Acta Neurol. Scand. 101 2000 159 164
18. G. Hebert, J. Arsaut, R. Dantzer, and J. Demotes-Mainard Time-course of the expression of inflammatory cytokines and matrix metalloproteinases in the striatum and mesencephalon of mice injected with 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine, a dopaminergic neurotoxin Neurosci. Lett. 349 2003 191 195
19. R.E. Heikkila, A. Hess, and R.C. Duvoisin Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice Science 224 1984 1451 1453
20. S. Hunot, and E.C. Hirsch Neuroinflammatory processes in Parkinson's disease Ann. Neurol. 53 2003 S49 S60
21. K. Kaku, T. Shikimi, Y. Kamisaki, K. Shinozuka, H. Ishino, H. Okunishi, and S. Takaori Elevation of striatal interleukin-6 and serum corticosterone contents in MPTP-treated mice Clin. Exp. Pharmacol. Physiol. 26 1999 680 683
22. K.W. Kelley, R.M. Bluthe, R. Dantzer, J.H. Zhou, W.H. Shen, R.W. Johnson, and S.R. Broussard Cytokine-induced sickness behavior Brain Behav. Immun. 17 Suppl. 1 2003 S112 S118
23. J.P. Konsman, P. Parnet, and R. Dantzer Cytokine-induced sickness behaviour: mechanisms and implications Trends Neurosci. 25 2002 154 159
24. R.J. Marttila, J. Eskola, M. Paivarinta, and U.K. Rinne Immune functions in Parkinson's disease Adv. Neurol. 40 1984 315 323
25. R.J. Marttila, J. Eskola, E. Soppi, and U.K. Rinne Immune functions in Parkinson's disease lymphocyte subsets, concanavalin A-induced suppressor cell activity and in vitro immunoglobulin production J. Neurol. Sci. 69 1985 121 131
26. F. McKenna, P.J. McLaughlin, B.J. Lewis, G.C. Sibbring, J.A. Cummerson, D. Bowen-Jones, and R.J. Moots Dopamine receptor expression on human T- and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study J. Neuroimmunol. 132 2002 34 40
27. E. Merlot, E. Moze, R. Dantzer, and P.J. Neveu Suppression of restraint-induced plasma cytokines in mice pretreated with LPS Stress 5 2002 131 135
28. M. Mogi, M. Harada, T. Kondo, P. Riederer, H. Inagaki, M. Minami, and T. Nagatsu Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients Neurosci. Lett. 180 1994 147 150
29. M. Mogi, M. Harada, P. Riederer, H. Narabayashi, K. Fujita, and T. Nagatsu Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients Neurosci. Lett. 165 1994 208 210
30. M. Mogi, A. Togari, M. Ogawa, K. Ikeguchi, N. Shizuma, D. Fan, I. Nakano, and T. Nagatsu Effects of repeated systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to mice on interleukin-1beta and nerve growth factor in the striatum Neurosci. Lett. 250 1998 25 28
31. P.J. Neveu Cerebral lateralization and the immune system Int. Rev. Neurobiol. 52 2002 303 323
32. P.J. Neveu, P. Barneoud, S. Vitiello, C. Betancur, and M. Le Moal Brain modulation of the immune system: association between lymphocyte responsiveness and paw preference in mice Brain Res. 457 1988 392 394
33. N. Quan, and M. Herkenham Connecting cytokines and brain: a review of current issues Histol. Histopathol. 17 2002 273 288
34. B. Saha, A.C. Mondal, J. Majumder, S. Basu, and P.S. Dasgupta Physiological concentrations of dopamine inhibit the proliferation and cytotoxicity of human CD4+ and CD8+ T cells in vitro: a receptor-mediated mechanism Neuroimmunomodulation 9 2001 23 33
35. M.V. Selikhova, N.E. Kushlinskii, N.V. Lyubimova, and E.I. Gusev Impaired production of plasma interleukin-6 in patients with Parkinson's disease Bull. Exp. Biol. Med. 133 2002 81 83
36. Y.Q. Shen, G. Hebert, L.Y. Lin, Y.L. Luo, E. Moze, K.S. Li, and P.J. Neveu Interleukine-1beta and interleukine-6 levels in striatum and other brain structures after MPTP treatment: influence of behavioral lateralization J. Neuroimmunol. 158 2005 14 25
37. G. Stypula, J. Kunert-Radek, H. Stepien, K. Zylinska, and M. Pawlikowski Evaluation of interleukins, ACTH, cortisol and prolactin concentrations in the blood of patients with Parkinson's disease Neuroimmunomodulation 3 1996 131 134
38. N.A. Tatton, and S.J. Kish In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining Neuroscience 77 1997 1037 1048